Halozyme Therapeutics

HALONasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$12.649 B

$111.45 -0.89%

Close of 21 Sept 2026

Revenue

$1.40B

#1340 by revenue

Earnings

$316.9M

#812 by earnings

Shares outstanding

113,498,000

Latest filing cover page

P/E ratio

39.9

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#8Neurocrine BiosciencesNBIX$14.6B
#9ExelixisEXEL$14.2B
#10Halozyme TherapeuticsHALO$12.6B
#11Bio-TechneTECH$11.4B
#12Twist BioscienceTWST$11.0B

What if Halozyme Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$266,736.45

Per share 2,393× higher

Bitcoin $1.72T

$15,152.72

Per share 136× higher

Nvidia $5.48T

$48,281.54

Per share 433× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Halozyme Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.